Question explored with the scientific record
Conversation so far
- 1 What causes heartburn?
- 2 How can I tell if my heartburn is acid, non-acid, or functional?
- 3 What are the best treatments if symptoms don’t match reflux on testing?
- 4 What are the most effective non-acid treatments, and their risks?
- 5 how can one address a sensitive esophagus
- 6 are antacids a good substitute for treating heartburn
- 7 how can one heal tissue in a sensitive esophgus
- 8 dietary changes and positional therapy for reflux events
- 9 does an H2 blocker help reflux events
- 10 safety of omeprazole for long term use
Answered on this page ↓
safety of omeprazole for long term use
The short version: long-term omeprazole use carries documented risks of magnesium depletion, vitamin B12 deficiency, and gastric cell changes, with the strongest cancer signal in people who also carry H. pylori.
The evidence here shows several well-documented harms from long-term omeprazole. A 2018 case report with a drug rechallenge confirmed that omeprazole can cause severe hypomagnesemia: the patient's magnesium fell to 0.69 mmol/L after one week back on the drug, despite oral magnesium supplements [1]. A 2012 case report shows the same pattern, with magnesium dropping as low as 0.29 mmol/L and requiring IV replacement [5]. Low magnesium can cause muscle cramps, heart rhythm problems, and seizures.
A 1998 study of Zollinger-Ellison patients on omeprazole for an average of 4.5 years found that 6% had low vitamin B12 levels [3]. The mechanism is straightforward: stomach acid is needed to release B12 from food, and omeprazole suppresses acid production.
The cancer signal is more complex. A 2024 review cites a Swedish cohort of nearly 800,000 people showing that long-term PPI use is a risk factor for gastric cancer, with higher risk from longer use [2]. A gerbil study found that omeprazole accelerated H. pylori-driven stomach cancer, while uninfected animals on the drug developed no cancer at all [4]. That suggests the risk depends on whether you carry H. pylori. A 1993 study of peptic ulcer patients found that after 5 years on omeprazole, the rate of atrophic gastritis rose from 1.8% to 20.8% [6]. Atrophic gastritis is a precursor to stomach cancer.
The evidence here is a mix of case reports, small cohort studies, and animal data. No large randomized trial has tracked all-cause mortality or cancer incidence in long-term omeprazole users versus untreated controls. The magnesium and B12 risks are well-supported by mechanism and case evidence. The cancer risk is real in H. pylori-positive people, but less clear for those without the infection.
My call: long-term omeprazole carries real risks of magnesium depletion, B12 deficiency, and gastric changes, with the strongest cancer signal in H. pylori carriers. Confidence: moderate.
Sources used 6
-
Functional hypoparathyroidism secondary to magnesium deficiency in long-term users of proton pump inhibitor
A long-term omeprazole user with severe hypomagnesemia had functional hypoparathyroidism and hypocalcemia; magnesium replacement normalized PTH and electrolytes, and omeprazole rechallenge reproduced hypomagnesemia, supporting PPI-induced magnesium deficiency as the cause.
DOI: 10.14341/osteo20173102-107 -
Gastric Cancer associated with the use of Omeprazole in Adults
Long-term omeprazole use in adults is reviewed for potential links to gastric cancer, focusing on histologic mucosal changes, hypergastrinemia, and Helicobacter pylori interactions.
DOI: 10.56294/piii2024332 -
Effect of Long-Term Gastric Acid Suppressive Therapy on Serum Vitamin B12 Levels in Patients with Zollinger-Ellison Syndrome
This study investigates the impact of long-term omeprazole treatment on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome, finding significant decreases in vitamin B12 levels associated with prolonged acid suppression.
DOI: 10.1016/S0002-9343(98)00087-4 -
Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil
In Mongolian gerbils, long-term omeprazole treatment accelerated Helicobacter pylori–driven gastric atrophy and cancer, whereas uninfected animals remained unaffected, highlighting potential risks of chronic PPI use in infected patients and supporting H. pylori eradication.
DOI: 10.1136/gut.2010.229286 -
Severe hypomagnesemia refractory to oral supplementation associated to omeprazole treatment
This study reports a case of severe hypomagnesemia in a patient undergoing long-term omeprazole treatment, highlighting the potential for proton pump inhibitors to cause magnesium deficiency that is refractory to oral supplementation.
DOI: 10.1016/j.endoen.2012.08.005 -
Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
This study investigates the long-term effects of omeprazole therapy on serum gastrin levels, endocrine cell growth, and gastritis in patients with peptic ulcer disease, revealing significant increases in gastrin levels and argyrophil cell hyperplasia correlated with gastritis se…
DOI: 10.1016/0016-5085(93)90344-c